An open-label, randomized, 48-week study to assess the safety, tolerability and activity of raltegravir when replacing the ritonavir-boosted PI [protease-inhibitor] component of HAART [highly active antiretroviral therapy] in HIV-infected individuals with viral load suppression on a ritonavir-boosted PI containing regimen

Trial Profile

An open-label, randomized, 48-week study to assess the safety, tolerability and activity of raltegravir when replacing the ritonavir-boosted PI [protease-inhibitor] component of HAART [highly active antiretroviral therapy] in HIV-infected individuals with viral load suppression on a ritonavir-boosted PI containing regimen

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Raltegravir (Primary) ; Antiretrovirals; Atazanavir; Darunavir; Fosamprenavir; HIV protease inhibitors; Indinavir; Lopinavir; Ritonavir; Saquinavir; Tipranavir
  • Indications HIV-1 infections
  • Focus Biomarker; Therapeutic Use
  • Acronyms SPIRAL
  • Most Recent Events

    • 08 Mar 2012 Biomarker and lipid profile results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
    • 22 Nov 2011 Results of the 86 patients included in the SPIRAL-LIP substudy have been reported in AIDS.
    • 18 Jul 2010 Results were presented at the 18th International AIDS Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top